Screener
United Therapeutics UTHR Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $783.3M-1.9% | $781.5M-1.6% | $790.2M+7.4% | $799.5M+6.8% | $798.6M+11.7% | ||
| $99.5M+13.6% | $133.4M+44.2% | $103.4M+36.2% | $100.9M+21.4% | $87.6M+12.6% | ||
| $683.8M-3.8% | $648.1M-7.7% | $686.8M+4.1% | $698.6M+4.9% | $711M+11.6% | ||
| 87.3%-1.7pp | 82.9%-5.4pp | 86.9%-2.8pp | 87.4%-1.5pp | 89%-0.1pp | ||
| $146.3M+9.2% | $138.2M-7.2% | $139.5M+4.3% | $127.5M+23.2% | $134M-4.0% | ||
| $206.7M-2.7% | $184.1M+8.2% | $190.6M+13.1% | $182.6M-16.7% | $212.5M+19.7% | ||
| $452.5M+4.2% | $455.7M+10.7% | $433.5M+14.6% | $411M+1.3% | $434.1M+9.9% | ||
| $330.8M-9.2% | $325.8M-14.9% | $356.7M-0.3% | $388.5M+13.2% | $364.5M+13.9% | ||
| 42.2%-3.4pp | 41.7%-6.5pp | 45.1%-3.5pp | 48.6%+2.8pp | 45.6%+0.9pp | ||
| $2.9M-60.3% | $3M-50.8% | $3.1M-60.8% | $3M-70.3% | $7.3M-37.1% | ||
| $41.9M-4.6% | -$7.5M-118% | $87.3M+125% | $49.5M+8.8% | $43.9M+24.0% | ||
| $372.7M-8.7% | $318.3M-24.8% | $444M+12.0% | $438M+12.7% | $408.4M+14.9% | ||
| $39.7M-59.9% | $43.4M-57.2% | $79.7M-16.3% | $99.3M+24.9% | $98.9M+28.1% | ||
| $333M+7.6% | $274.9M-14.7% | $364.3M+20.9% | $338.7M+9.6% | $309.5M+11.3% | ||
| 42.5%+3.8pp | 35.2%-5.4pp | 46.1%+5.2pp | 42.4%+1.1pp | 38.8%-0.1pp | ||
| $7.27+13.4% | $5.82-12.2% | $7.69+23.8% | $7.16+12.1% | $6.41+9.6% | ||
| $355M-7.9% | $348.4M-13.5% | $379.5M+0.6% | $410.4M+13.3% | $385.6M+13.9% | ||
| 45.3%-3.0pp | 44.6%-6.1pp | 48%-3.3pp | 51.3%+3.0pp | 48.3%+0.9pp | ||
| $330.8M-9.2% | $325.8M-14.9% | $356.7M-0.3% | $388.5M+13.2% | $364.5M+13.9% |
FAQ
- What is United Therapeutics's revenue?
- United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 2.5% year over year.
- Is United Therapeutics profitable?
- United Therapeutics reported $1.3B in net income over the trailing twelve months, a 41.6% net margin.
- What are United Therapeutics's profit margins?
- Gross margin is 86.1% and operating margin is 44.4%, with a 41.6% net margin.
- What is United Therapeutics's earnings per share?
- United Therapeutics's diluted EPS over the trailing twelve months is $27.94.
- Where does United Therapeutics's income statement data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
